Cochlear Implants’ Impact on Tinnitus Relief

A significant majority of patients with bothersome tinnitus experienced clinically meaningful improvement after receiving a cochlear implant, according to a new Japanese study. However, the research found no extra benefit for bilateral implantation over a single implant, and longer daily device use did not show a clear dose-response effect on tinnitus reduction.

Study Design: Measuring Tinnitus Before and After Implantation

Researchers from Nagoya University Graduate School of Medicine conducted a retrospective analysis of 61 patients with hearing loss who underwent cochlear implantation. The team, led by Masatoshi Hasegawa, aimed to clarify the effect of implantation on tinnitus and to compare outcomes between unilateral and bilateral procedures.

All patients completed standard tinnitus evaluations both before and after their surgery. The primary tool was the Tinnitus Handicap Inventory (THI), a validated questionnaire that quantifies the functional, emotional, and catastrophic impact of tinnitus. Patients also rated their tinnitus loudness and distress on a Visual Analog Scale (VAS). The researchers analyzed changes in these scores, with a THI score reduction of 7 points or more defined as a clinically meaningful improvement.

Ten patients who reported no tinnitus (a THI score of 0) both before and after surgery were excluded from the change analysis. None of the 61 patients developed new tinnitus post-operatively.

Tinnitus Improvement is Common, But Not Guaranteed

The core finding centers on the 51 patients included in the tinnitus change analysis. Within this group, 36 patients had bothersome pre-operative tinnitus, defined by a THI score of 7 or higher.

The results were positive for this group. Thirty-two of these 36 patients (89%) showed a clinically meaningful improvement in their THI scores after implantation. Four patients reported no change. For the 15 patients with mild, pre-existing tinnitus (THI < 7), the condition remained stable for 14, while one patient reported a worsening of symptoms.

“This data supports the existing body of evidence that cochlear implantation can be a very effective intervention for reducing tinnitus burden in suitable candidates,” said Hasegawa. The mechanism is not fully understood but is thought to involve the restoration of auditory input, which may help counteract the neural hyperactivity associated with tinnitus.

One Implant or Two? No Difference for Tinnitus

A central question for clinicians and patients considering cochlear implants is whether two implants offer benefits beyond one, particularly for conditions like tinnitus. This study directly addressed that question and found a clear answer regarding tinnitus: no significant difference.

The analysis showed that whether patients received a unilateral or bilateral cochlear implant, their outcomes on the THI and VAS loudness scales were statistically similar. This suggests that the therapeutic effect on tinnitus is driven by the stimulation from a single implant, and adding a second does not amplify the reduction in perception or handicap. This finding is important for clinical decision-making and patient counseling, as it indicates that the potential tinnitus benefit is not a primary factor in arguing for bilateral implantation.

For other aspects of hearing, such as sound localization and understanding speech in noise, bilateral implants are known to provide significant advantages. The study’s conclusion is specific to the outcome of tinnitus suppression.

The Role of Device Use Time

The researchers also investigated whether the amount of time patients wore their sound processors each day influenced their tinnitus outcomes. They found a significant relationship for one specific measure: distress. Patients who used their devices for longer periods tended to report greater reductions in tinnitus-related distress on the VAS.

However, this pattern did not extend to the objective measure of tinnitus loudness or to the comprehensive THI score. The lack of a consistent exposure-response relationship across all metrics indicates that while regular use is beneficial, simply wearing the processor for more hours does not directly correlate with a linear decrease in tinnitus perception. This points to the complexity of the condition, where psychological adaptation and neural plasticity play roles distinct from the constant of auditory stimulation.

This nuanced finding aligns with other therapeutic approaches for tinnitus, such as Cognitive Behavioral Therapy (CBT), which focuses on managing the reaction to tinnitus rather than eliminating the sound itself.

Practical Implications for Patients and Clinicians

This study offers several concrete points for the hearing health community. First, it provides strong evidence that cochlear implantation is a viable treatment path for patients with severe hearing loss and co-existing bothersome tinnitus, with a high likelihood of improvement. The absence of new-onset tinnitus is also a reassuring safety datum.

Second, it clarifies that the decision for unilateral versus bilateral implantation should be based on traditional audiologic reasons—like improved spatial hearing and binaural summation—rather than an expectation of superior tinnitus suppression from two implants.

Finally, the results support encouraging consistent daily use of the cochlear implant sound processor, as this is linked to managing the distress component of tinnitus. Patients should have realistic expectations that improvement is common, but the relationship between use time and symptom reduction is not strictly proportional.

For individuals with tinnitus but different hearing profiles, such as those with hidden hearing loss, cochlear implantation is not indicated. Their management may involve other emerging strategies, including neurofeedback or specialized sound therapies.

The full research paper, “Tinnitus outcomes after unilateral and bilateral cochlear implantation,” by Hasegawa et al., is available in Acta Otolaryngologica (DOI: 10.1080/00016489.2026.2699324, PMID: 42532031).